These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 30464690)
21. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421 [TBL] [Abstract][Full Text] [Related]
22. [Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer]. Liu X; Zhong D Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272 [TBL] [Abstract][Full Text] [Related]
23. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. Joshi M; Rice SJ; Liu X; Miller B; Belani CP PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985 [TBL] [Abstract][Full Text] [Related]
24. Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia). Sakai T; Matsumoto S; Ueda Y; Shibata Y; Ikeda T; Nakamura A; Kodani M; Ohashi K; Furuya N; Izumi H; Nosaki K; Umemura S; Zenke Y; Udagawa H; Sugiyama E; Yoh K; Goto K J Thorac Oncol; 2023 Nov; 18(11):1538-1549. PubMed ID: 37543207 [TBL] [Abstract][Full Text] [Related]
25. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant Advanced Non-small Cell Lung Cancer]. Li N; Xu Y; Fan Y Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):714-722. PubMed ID: 34696543 [TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. Paik PK; Arcila ME; Fara M; Sima CS; Miller VA; Kris MG; Ladanyi M; Riely GJ J Clin Oncol; 2011 May; 29(15):2046-51. PubMed ID: 21483012 [TBL] [Abstract][Full Text] [Related]
27. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S; Cancer Treat Rev; 2022 Feb; 103():102335. PubMed ID: 35033867 [TBL] [Abstract][Full Text] [Related]
28. Vemurafenib in non-small-cell lung cancer patients with BRAF Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346 [TBL] [Abstract][Full Text] [Related]
29. BRAF-mutations in non-small cell lung cancer. Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757 [TBL] [Abstract][Full Text] [Related]
30. Molecular alterations in non-small cell lung carcinomas of the young. VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236 [TBL] [Abstract][Full Text] [Related]
31. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF. Seto K; Haneda M; Masago K; Fujita S; Kato S; Sasaki E; Hosoda W; Murakami Y; Kuroda H; Horio Y; Hida T; Okubo K; Yatabe Y Pathol Int; 2020 May; 70(5):253-261. PubMed ID: 31970865 [TBL] [Abstract][Full Text] [Related]
32. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. Leonetti A; Facchinetti F; Rossi G; Minari R; Conti A; Friboulet L; Tiseo M; Planchard D Cancer Treat Rev; 2018 May; 66():82-94. PubMed ID: 29729495 [TBL] [Abstract][Full Text] [Related]
33. Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma. Hwang I; Choi YL; Lee H; Hwang S; Lee B; Yang H; Chelakkot C; Han J Cancer Res Treat; 2022 Jul; 54(3):782-792. PubMed ID: 34844291 [TBL] [Abstract][Full Text] [Related]
34. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. Marchetti A; Felicioni L; Malatesta S; Grazia Sciarrotta M; Guetti L; Chella A; Viola P; Pullara C; Mucilli F; Buttitta F J Clin Oncol; 2011 Sep; 29(26):3574-9. PubMed ID: 21825258 [TBL] [Abstract][Full Text] [Related]
35. Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study. Wang W; Gu X; Si J; Pu X; Wang L; Chen H; Xu C; Zhang X; Yuan H; Lou G; Shao L; Zhang G; Song Z Genes Chromosomes Cancer; 2022 Sep; 61(9):530-541. PubMed ID: 35396765 [TBL] [Abstract][Full Text] [Related]
36. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. Hamard C; Ruppert AM; Lavole A; Rozensztajn N; Antoine M; Cadranel J; Wislez M Ann Pathol; 2016 Jan; 36(1):63-72. PubMed ID: 26775573 [TBL] [Abstract][Full Text] [Related]
37. A BRAF new world. Frisone D; Friedlaender A; Malapelle U; Banna G; Addeo A Crit Rev Oncol Hematol; 2020 Aug; 152():103008. PubMed ID: 32485528 [TBL] [Abstract][Full Text] [Related]